4-溴-2-环丁氧基吡啶 | 1142194-51-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-溴-2-环丁氧基吡啶
• 英文名称: 4-bromo-2-cyclobutoxypyridine
• 英文别名: 4-bromo-2-cyclobutyloxypyridine
• CAS: 1142194-51-1
• 化学式: C₉H₁₀BrNO
• 分子量: 228.088
• InChiKey: YEEMCNZWYCOAFW-UHFFFAOYSA-N

物化性质

• 沸点：
  272.9±20.0 °C(Predicted)
• 密度：
  1.521±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-溴-2-环丁氧基吡啶 在 正丁基锂 、 二乙胺基三氟化硫 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 4-[trans-3-(benzyloxy)-1-fluorocyclobutyl]-2-(cyclobutyloxy)pyridine
  参考文献：
  名称：

  [EN] HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS
  [FR] COMPOSÉS D'HYDROXY ISOXAZOLE UTILES EN TANT QU'AGONISTES DE GPR120

  摘要：

  本发明涉及一种由公式（I）表示的化合物：以及所述化合物的药学可接受的盐，作为用于治疗或预防糖尿病、高脂血症、肥胖、非酒精性脂肪肝炎（NASH）、炎症相关疾病及相关疾病和状况的有用物质。这些化合物作为G蛋白偶联受体GPR120的激动剂是有用的。还包括药物组合物和治疗方法。

  公开号：

  WO2018107415A1

文献信息

• [EN] THIOPHENE COMPOUNDS WITH CYCLIC AMIDES, AND USES THEREOF<br/>[FR] COMPOSÉS THIOPHÈNE AYANT DES AMIDES CYCLIQUES, ET LEURS UTILISATIONS
  申请人：CAPULUS THERAPEUTICS LLC

  公开号：WO2021097123A1

  公开（公告）日：2021-05-20

  Provided herein are compounds comprising a four-ring core, such as compounds of Formula (I) and Formula (II), and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using these compounds, or pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.

  本文提供了包含四环核心的化合物，例如Formula (I)和Formula (II)的化合物，以及这些化合物的药用盐、溶剂合物、互变异构体、同位素或同分异构体。本文还提供了使用这些化合物或其药用盐、溶剂合物、互变异构体、同位素或同分异构体来抑制类固醇调节元件结合蛋白（SREBP）途径的组分的方法，例如SREBP或SREBP裂解激活蛋白（SCAP）。此外，还提供了治疗患有肝病、非酒精性脂肪肝、胰岛素抵抗或癌症等疾病的方法。
• Hydroxy isoxazole compounds useful as GPR120 agonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10864211B2

  公开（公告）日：2020-12-15

  The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

  本发明涉及一种由式（I）代表的化合物：及其药学上可接受的盐被公开用于治疗或预防糖尿病、高脂血症、肥胖症、NASH、炎症相关疾病以及相关疾病和病症。这些化合物可作为 G 蛋白偶联受体 GPR120 的激动剂。还包括药物组合物和治疗方法。
• HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3555055A1

  公开（公告）日：2019-10-23
• [EN] HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS<br/>[FR] COMPOSÉS D'ISOXAZOLE HYDROXY UTILES EN TANT QU'AGONISTES DU GPR120
  申请人：MERCK SHARP & DOHME

  公开号：WO2018111734A1

  公开（公告）日：2018-06-21

  The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
• [EN] BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE<br/>[FR] COMPOSÉS CIBLANT BRM ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2019195201A1

  公开（公告）日：2019-10-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand that binds to the Von Hippel-Lindau E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.